8-K
filed November 15, 2023, 6:59 PM ET
ticker BIAF
CIK 0001712762
earnings
confidence high
sentiment neutral
materiality 0.65
bioAffinity Q3 revenue surges to $298K on PPLS acquisition; net loss narrows to $2.3M
bioAffinity Technologies, Inc.
2023-Q3 EPS reported
-$0.65
revenue$320,895
- Revenue of $298,484 for Q3 2023, up from $1,150 in prior year, primarily from acquired PPLS lab.
- Net loss of $2.3M ($0.26 per share) vs $4.9M ($1.17) in prior year; cash at $4.5M down from $11.4M.
- Acquired non-medical assets of Village Oaks Pathology Services on Sept 18, 2023; PPLS forecast to contribute $8.7M net revenue over next 12 months.
- CMS issued preliminary payment decision for CyPath Lung; final expected Nov 2023 with effective date Jan 1, 2024.
- Revenue outlook for full year 2023: $2.1-$2.3M; next 12 months: $8.4-$9.0M.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.4
bioAffinity Technologies, Inc. reported financial results for quarter ended September 30, 2023.
- Period
- quarter ended September 30, 2023
- Result
- reported results
Exact text from the filing
On November 14, 2023, bioAffinity Technologies, Inc., a Delaware corporation (the "Registrant"), issued a press release that included financial information for its quarter ended September 30, 2023.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.7
bioAffinity Technologies, Inc. reported three and nine months ended Sept. 30, 2023 results: revenue $298,484, EPS $0.26 per share. Guidance reaffirmed.
- Period
- three and nine months ended Sept. 30, 2023
- Revenue
- $298,484
- EPS
- $0.26 per share
- Guidance
- reaffirmed
- Result
- reported results
Exact text from the filing
with larger medical systems, we anticipate substantial revenue growth for CyPath ® Lung.” Third Quarter Financial Results Revenue for the third quarter of 2023 increased to $298,484, up from $1,150 in the prior-year period. Prior to the Sept. 18, 2023, acquisition of PPLS, bioAffinity Technologies’ revenue was generated from royalties from sales of CyPath ®
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.